StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO)

StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note released on Thursday morning. The firm issued a sell rating on the biotechnology company’s stock.

APTO has been the topic of a number of other reports. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Aptose Biosciences in a report on Wednesday, February 12th. Alliance Global Partners upgraded shares of Aptose Biosciences to a “strong-buy” rating in a research note on Thursday, February 27th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Aptose Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $130.00.

Aptose Biosciences Stock Up 6.0 %

Shares of NASDAQ APTO opened at $3.70 on Thursday. The firm has a market cap of $7.92 million, a P/E ratio of -1.25 and a beta of 1.14. Aptose Biosciences has a twelve month low of $2.39 and a twelve month high of $51.61. The company has a 50 day moving average of $4.63 and a 200 day moving average of $7.59.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp boosted its position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 75.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 703,384 shares of the biotechnology company’s stock after purchasing an additional 301,634 shares during the period. Sigma Planning Corp owned about 1.17% of Aptose Biosciences worth $158,000 as of its most recent SEC filing. 26.62% of the stock is currently owned by institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.